Eribulin treatment for patients with metastatic breast cancer: The United Kingdom experience-a multicenter retrospective study

Abstract

Purpose: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK. Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS). Results: Among 577 patients analyzed, the median age was 56 years and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315) and the PFS was 117 days (95% CI: 105-129). Median OS was higher among older patients (≥ 65 vs < 65 years: 325 days [95% CI: 264-385] vs 285 days [95% CI: 252-317]; P = 0.028). Median OS was also higher in patients that received eribulin after fewer prior lines of chemotherapy (≤ 2 vs > 2 prior: 328 days [95% CI: 264-385] vs 264 days [95% CI: 229-298]; P = 0.042). Conclusions: These retrospective data suggest eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings which, while predictable, supports consideration of eribulin as a second-line treatment option.